| Bioactivity | SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma[1]. |
| Invitro | SK-216 (0-50 μM, 48 h) 可以以剂量依赖的方式抑制 143B 细胞的侵袭，但不影响细胞增殖和迁移[1]。 Western Blot Analysis [1] Cell Line: |
| In Vivo | SK-216（i.p.，6.6 μg / 200 μL in PBS，每 3 天一次）在 143B-Luc 细胞感染雄性无胸腺裸鼠模型中，可以抑制人骨肉瘤细胞的肺转移，但不能抑制原发灶的肿瘤生长[1]。 Animal Model: |
| Name | SK-216 |
| CAS | 654080-03-2 |
| Formula | C29H29NNa2O6 |
| Molar Mass | 533.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Minori Tsuge, et al. SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma. Int J Mol Sci. 2018 Mar 5;19(3):736. |